海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02637 海西新药

未开盘 09-23 16:08:14

175.600

+0.300

+0.17%

最高179.900	最低175.500	成交量4.00万
今开178.000	昨收175.300	日振幅2.51%
总市值138.21亿	流通市值138.21亿	总股本7,871万
成交额710.15万	换手率0.05%	流通股本7,871万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":175.6,"timestamp":1790150894008,"preClose":175.3,"halted":0,"volume":39950,"delay":0,"changeRate":0.0017113519680546658,"floatShares":78707270,"shares":78707270,"eps":2.9801168673281304,"marketStatus":"未开盘","change":0.3,"latestTime":"09-23 16:08:14","open":178,"high":179.9,"low":175.5,"amount":7101480,"amplitude":0.0251,"askPrice":176.8,"askSize":750,"bidPrice":175.6,"bidSize":450,"shortable":3,"etf":0,"ttmEps":2.3335939527040277,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790213400000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":175.3,"openAndCloseTimeList":[[1790127000000,1790136000000],[1790139600000,1790150400000]],"volumeRatio":0.2277474493007971,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02637","defaultTab":"news","newsList":[{"id":"2667834319","title":"海西新药(02637)：HX9428用于治疗nAMD的I期临床研究已完成24周治疗数据观察 II期剂量扩展研究取得阶段性临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2667834319","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667834319?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:26","pubTimestamp":1789561585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，HX9428用于治疗新生血管性年龄相关性黄斑变性的中国I期临床研究已完成24周治疗数据观察;中国II期剂量扩展研究目前仍在进行中，并已取得阶段性临床数据。HX9428中国I期临床研究共纳入15例nAMD患者，覆盖5 mg/QD至40 mg/QD五个剂量组。HX9428中国II期剂量扩展研究目前仍在进行中。公司将持续监测各项安全性指标，并进一步评估HX9428的长期获益风险特征。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海西新药(02637)：HX9428用于治疗nAMD的I期临床研究已完成24周治疗数据观察 II期剂量扩展研究取得阶段性临床数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181985415","title":"海西新药（02637）公布HX9428治疗nAMD I期及II期阶段性临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1181985415","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181985415?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:25","pubTimestamp":1789561531,"startTime":"0","endTime":"0","summary":"2026年9月16日，福建海西新药创制股份有限公司发布自愿公告，更新口服小分子候选药物HX9428用于新生血管性年龄相关性黄斑变性的中国I期及II期临床研究进展。截至2026年8月14日，5 mg/QD、10 mg/QD及20 mg/QD三组共入组80例患者，其中约78%为既往接受anti-VEGF治疗患者，约22%为初治患者；45例已完成第13周访视，11例已完成24周治疗。公告提示，HX9428尚未获得任何国家或地区药品监管机构批准上市，临床研究仍在进行中。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617679","title":"创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617679","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617679?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:20","pubTimestamp":1789525259,"startTime":"0","endTime":"0","summary":"消息面上，国金证券表示，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。诚通证券表示，2025年为创新药海外授权BD大年，2026H1我国创新药海外授权BD交易继续大幅增长，总交易金额已接近1000亿美元，国产创新药已从偶发性出海转变为系统性趋势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991724","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","LU0348827113.USD","LU2488822045.USD","LU2097828805.USD","BK0183","LU0561508036.HKD","LU2580892789.USD","LU0128526141.USD","BK0060","IE00BZ08YS42.EUR","LU0140636845.USD","LU0516422952.EUR","LU0516423174.USD","KURE","LNGR","LU1255011170.USD","600276","BK0239","LU0417516902.SGD","IE00B0JY6N72.USD","LU0348825331.USD","LU1023057109.AUD","LU1997244956.HKD","BK1574","LU2039709279.SGD","LU2148510915.USD","LU1328615791.USD","IBBQ","09688","02637","BK1515","01177","LU2097828557.USD","02269","LU0327786744.USD","LU0359201612.USD","LU0588546209.SGD","LU0307460666.USD","159992","LU0456846285.SGD","01276","MEDX","LU1580142542.USD","LU1820825898.SGD","BK0188","06978","LU1655091616.SGD","01477","LU0043850808.USD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667148376","title":"港股异动 | 海西新药(02637)涨超3% 近期已递交HX9428的DME IIa期新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2667148376","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667148376?lang=zh_cn&edition=full","pubTime":"2026-09-15 14:48","pubTimestamp":1789454932,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药涨超3%，截至发稿，涨2.89%，报195.5港元，成交额618.26万港元。消息面上，海西新药发布公告，本公司自主研发的创新药项目HXP056的候选药物分子HX9428，已于2026年8月31日正式向中国国家药品监督管理局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。公司表示，将继续全力推进HX9428在中美两地多项临床研究的进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","BK1191","BK4585","KCAI","BK4588","BMED","IBBQ","02637","VXUS","PSYK","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666530067","title":"【券商聚焦】国投证券首予海西新药（02637）“买入-A”评级 指口服眼药潜力大","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530067","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666530067?lang=zh_cn&edition=full","pubTime":"2026-09-09 14:15","pubTimestamp":1788934513,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券发布研报指，海西新药 核心产品口服VEGFR2小分子HXP056存在颠覆眼底病治疗标准的潜力，有望凭口服优势抢占当前注射眼药市场份额。采用DCF法估值，假设10.0%折现率、2.0%永续增长率，得到公司价值约192.7亿元人民币，对应目标价266.80港元，首次给予买入-A评级。风险提示包括HXP056安全性不及预期、临床开发进度及结果不及预期、产品销售放量不及预期及计算假设不及预期风险。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991157","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","02637","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819950","title":"海西新药：已提交自研创新药HX9428临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819950","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819950?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:53","pubTimestamp":1788349980,"startTime":"0","endTime":"0","summary":"9月2日，海西新药（02637）发布公告，公司自主研发的创新药项目HXP056之候选药物分子HX9428，已于2026年8月31日正式向国家药监局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。HX9428是海西新药自主研发的全新口服小分子创新药物，拟用于治疗nAMD、DME及RVO等血管性视网膜相关疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862943252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862943252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02637","LNGR","MEDX","BK1191","PSYK","MDTX","IBBJ","BK1161","06978","BK1574","BMED","159992","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134622913","title":"海西新药（02637）口服眼底药HX9428完成nAMD一期临床并向NMPA递交DME二期IND","url":"https://stock-news.laohu8.com/highlight/detail?id=1134622913","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134622913?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:22","pubTimestamp":1788348136,"startTime":"0","endTime":"0","summary":"2026年9月2日，海西新药公布，其自主研发的候选药物HX9428已于2026年8月31日向中国国家药品监督管理局药品审评中心递交糖尿病性黄斑水肿IIa期临床试验申请。该适应症为HX9428推进的第二个开发方向。HX9428为口服小分子药物，拟用于nAMD、DME及视网膜静脉阻塞等血管性视网膜疾病。截至公告日期，HX9428尚未获得任何监管机构上市批准，其安全性与有效性仍需进一步临床验证。公司提醒投资者，创新药研发存在高风险，HX9428能否最终获批上市尚存在不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664681635","title":"海西新药(02637)：HX9428顺利完成新生血管性年龄相关性黄斑变性(nAMD)之I期临床研究并递交新适应症糖尿病性黄斑水肿(DME)之IIa 期新药临床试验申请(IND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664681635","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664681635?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:18","pubTimestamp":1788347924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，本公司自主研发的创新药项目HXP056之候选药物分子HX9428，已于2026年8月31日正式向中国国家药品监督管理局 药品审评中心递交新适应症糖尿病性黄斑水肿的 IIa期新药临床试验申请。上述初步数据显示HX9428具有良好的安全性特征及潜在疗效信号，其安全性及有效性尚需透过进一步临床研究予以验证。本公司将继续全力推进HX9428在中美两地多项临床研究的进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","PSYK","BK1191","IBBQ","IND","BMED","02637","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105163555","title":"海西新药8月股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1105163555","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105163555?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:11","pubTimestamp":1788343906,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司于2026年9月2日发布2026年8月31日止月份的证券变动月报表。公告显示，公司于8月无新增发行、购回或注销股份活动，股本保持稳定。公司表示，其8月末已符合适用的香港联交所规定的最低公众持股量要求。综上所述，截至8月末，公司股本维持不变。本次公告由联席公司秘书张俊环代表公司签署，体现公司遵守香港联交所《上市规则》及相关法规的合规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662096704","title":"海西新药(02637.HK)发布中期业绩，归母净利润8104.87万元，同比下降24.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662096704","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662096704?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:58","pubTimestamp":1787925522,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151369016","title":"海西新药2026年中期业绩：营收3.12亿元，净利润0.81亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151369016","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151369016?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:47","pubTimestamp":1787921254,"startTime":"0","endTime":"0","summary":"海西新药公布截至2026年6月30日止六个月的财务数据显示，期内营收为3.12亿元，同比增长3.85%。同期净利润为0.81亿元，同比下降24.82%。研发投入达0.41亿元，占营收比重约13.08%，同比上升50.32%。本期销售与管理费用合计约1.12亿元，其中销售费用微降0.49%，管理费用增长9.41%。根据财报列示的营业收入与营业成本测算，毛利率约为81.90%，经营利润率约27.05%。海西新药主要业务涵盖创新药分部与仿制药分部。HXP089则获准在中国开展治疗胶质母细胞瘤的临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"海西新药2026年中期业绩：营收3.12亿元，净利润0.81亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140072246","title":"财报前瞻｜海西新药本季度营收预测缺失，机构观点待跟进","url":"https://stock-news.laohu8.com/highlight/detail?id=1140072246","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140072246?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:38","pubTimestamp":1787279910,"startTime":"0","endTime":"0","summary":"海西新药将于2026年08月28日披露最新季度财报，当前公开信息对关键指标缺乏一致预测，市场关注主营业务韧性与盈利质量变化。由于缺乏可获取的市场一致预期与公司指引，当前未能找到关于本季度营收、毛利率、净利润或净利率、调整后每股收益的具体预测及同比数据。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜海西新药本季度营收预测缺失，机构观点待跟进","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125396547","title":"港股创新药概念股盘初活跃，金斯瑞生物科技、海西新药涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125396547","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125396547?lang=zh_cn&edition=full","pubTime":"2026-08-18 09:35","pubTimestamp":1787016939,"startTime":"0","endTime":"0","summary":"8月18日，港股创新药概念股盘初活跃，$金斯瑞生物科技(01548)$、$海西新药(02637)$涨超8%，$药明生物(02269)$、$云顶新耀(01952)$、$百济神州(06160)$、$药明合联(02268)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","LU0348735423.USD","LU1794554557.SGD","02269","LU1880383366.USD","BK4585","LU0823426308.USD","KCAI","BK1191","LU0588546209.SGD","LU0128526141.USD","SG9999002562.SGD","HK0000320223.HKD","ONC","BK1589","BK1141","LU0043850808.USD","BK4588","LU0417516902.SGD","LU0359202008.SGD","VXUS","LU0979878070.USD","LU0456846285.SGD","01548","LU0320764599.SGD","LU0572944931.SGD","LU0348825331.USD","LU0708995583.HKD","LU0052750758.USD","LU2488822045.USD","BK1161","BK1521","LU0359201612.USD","LU0823426480.USD","LU1242518931.SGD","LU0516422952.EUR","LU2039709279.SGD","LU0327786744.USD","LU0516423174.USD","LU0516423091.SGD","LU0819121731.USD","LU0039217434.USD","LU0326950275.SGD","LU0029874061.USD","02637","BK1576","BK4526","HK0000306701.USD","LU1242518857.USD","BK1574","02268","HK0000306685.HKD","HK0000320264.USD","BK1610","LU0051755006.USD","LU0456827905.SGD","LU0307460666.USD","LU0516422440.USD","LU1688375341.USD","SG9999014674.SGD","IE00B0JY6N72.USD","LU1720050803.USD","LU0181495838.USD","BK4139","LU0417516738.SGD","SG9999002463.SGD","LU0856984785.SGD","BK1583","01952","LU3063872942.SGD","KURE","LU0516422366.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660045569","title":"港股异动 | 海西新药(02637.HK)早盘涨超12% 创新药HX9428获FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2660045569","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660045569?lang=zh_cn&edition=full","pubTime":"2026-08-18 09:33","pubTimestamp":1787016811,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","BK1574","02637","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193242998","title":"海西新药(02637)：口服候选药HX9428获美国FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1193242998","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193242998?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:51","pubTimestamp":1786967491,"startTime":"0","endTime":"0","summary":"2026年8月17日，海西新药全称福建海西新药创制股份有限公司发布自愿公告称，其自主研发的创新药项目HXP056之候选分子HX9428已获美国食品药品监督管理局授予快速通道资格，适应症为新生血管性年龄相关性黄斑变性。\\n\\n根据公告，FTD将使HX9428在临床开发全流程可与FDA开展高频、及时的沟通交流，并具备后续申请优先审评、加速批准及滚动审评等政策支持，或可加速全球临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482197","title":"海西新药(02637)：HX9428用于治疗新生血管性年龄相关性黄斑变性获美国FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482197","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660482197?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:50","pubTimestamp":1786967418,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，公司自主研发的创新药项目HXP056的候选药物分子HX9428，获美国食品药品监督管理局授予快速通道资格，用于开发治疗新生血管性年龄相关性黄斑变性。HX9428是海西新药自主研发的全新口服小分子创新药物，拟用于治疗nAMD。海外研发同步落地，HX9428已获FDA批准在美国开展nAMD适应症II期临床试验，公司正全力推进美国临床开发布局，以期早日惠及全球患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4585","02637","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144435453","title":"海西新药Hx9428获美国FDA快速通道认定，瞄准新生血管性年龄相关性黄斑变性治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1144435453","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144435453?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:48","pubTimestamp":1786967309,"startTime":"0","endTime":"0","summary":"福建海西新药股份有限公司传来重磅消息——其在研药物Hx9428已正式获得美国食品药品监督管理局（FDA）授予的快速通道资格认定，适应症指向新生血管性年龄相关性黄斑变性这一棘手的眼科疾病。这一认定不仅意味着该药物有望加速研发进程，更凸显了海西新药在创新药赛道上的前瞻布局与研发实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173380078","title":"港股创新药概念股盘中走强，和黄医药涨超7%，药明生物、金斯瑞生物科技涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173380078","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173380078?lang=zh_cn&edition=full","pubTime":"2026-08-17 10:08","pubTimestamp":1786932515,"startTime":"0","endTime":"0","summary":"8月17日，港股创新药概念股盘中走强，$和黄医药(00013)$涨超7%，$药明生物(02269)$、$海西新药(02637)$、$金斯瑞生物科技(01548)$涨超5%，$药明康德(02359)$、$药明合联(02268)$涨超4%，$信达生物(01801)$、$石药集团(01093)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1521","06978","LU0455707207.USD","LU0516423091.SGD","LU0856984785.SGD","LU1807302812.USD","LU2097828557.USD","LU0819121731.USD","LU3063872942.SGD","01801","LU0348766576.USD","HK0000306685.HKD","HK0000320264.USD","01093","IE00B5MMRT66.SGD","LU0039217434.USD","LU0320764599.SGD","LU0979878070.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU2488822045.USD","LU2097828631.EUR","VXUS","LU1720050803.USD","LU0516422952.EUR","LU2045819591.USD","LU0348735423.USD","IE0008368742.USD","LU0456827905.SGD","LU1226288170.HKD","LU1226287875.USD","IE0008369823.USD","IE00BZ08YT58.USD","LU0327786744.USD","LU2097828474.EUR","LU2328871848.SGD","LU0516422440.USD","159992","IE00B0JY6N72.USD","LU1969619763.USD","LU0029874061.USD","KURE","LU1152091754.HKD","LU0417516902.SGD","LU0140636845.USD","BK4585","02359","SG9999002463.SGD","LU1794554557.SGD","LU2125910500.SGD","LU0516422366.SGD","LU0502904849.HKD","BK1588","LU0417516738.SGD","LU1813983027.USD","LU0315179316.USD","LU0708995583.HKD","LU1688375341.USD","LU0314109678.HKD","LU1226288253.USD","LU1242518931.SGD","LU0181495838.USD","HK0000320223.HKD","LU0501845795.SGD","LU1046422090.SGD","SG9999004220.SGD","BK1574","01548","LU1008478684.HKD","LU0043850808.USD","LU1242518857.USD","LU0572944931.SGD","LU0326950275.SGD","LU1328277881.USD","LU0469268626.HKD","BK1587","HCM","LU0244354667.USD","LU0359202008.SGD","LU1226287529.USD","LU2242644610.SGD","LU0051755006.USD","LU0823426308.USD","LU0348767384.USD","MEDX","BK1576","LU2097828805.USD","BK1161","SG9999014674.SGD","LU0359201612.USD","LU2097828714.EUR","LU0823426480.USD","02637","00013","LU1188198961.HKD","LU0307460666.USD","LU0128526141.USD","LU1993786604.SGD","LU0348825331.USD","LU1960683339.HKD","LU0072913022.USD","BK1141","LU0456846285.SGD","LU1226287792.SGD","LU1152091168.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","IE00B543WZ88.USD","LU2039709279.SGD","KCAI","IE00B031HY20.USD","HK0000165453.HKD","HK0000306701.USD","LU0516423174.USD","02268","BK1610","BK4588","02269","BK4007","LNGR","BK1191","LU0588546209.SGD","LU1880383366.USD","LU0052750758.USD","LU0463099449.HKD","SG9999002562.SGD","IBBQ","BK1589","BK1583","BK4531","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126530849","title":"海西新药（02637）拟于8月28日召开董事会审议中期业绩及分红事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1126530849","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126530849?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:46","pubTimestamp":1786527969,"startTime":"0","endTime":"0","summary":"海西新药（02637）8月12日在港交所公告称，公司董事会将于2026年8月28日（星期五）召开会议，主要议程包括：一、审议及批准集团截至2026年6月30日止六个月的中期业绩并发布；二、讨论及建议派付中期股息（如有）；三、处理其他相关事项。\n公告显示，董事会目前由九名董事组成，包括五名执行董事康心汕、Feng Yan、Chen Guangming、李俊青及陈廷泽；一名非执行董事许冬；以及三名独立非执行董事王珊珊、蒲美婷和林斌。\n公司执行董事、董事长兼总经理康心汕代表董事会签署了本次公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146170998","title":"海西新药（02637）发布补充公告　详释更换外聘核数师原因及后续审计安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1146170998","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146170998?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:16","pubTimestamp":1786446985,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司8月11日发布有关建议更换外聘核数师的补充公告，披露具体时间轴、审计师遴选过程及后续审计计划，并重申与原审计师德勤—关黄陈方会计师行不存在任何意见分歧。公司强调，更换外聘核数师乃应对持续出现的外部监管及融资需求而作出的审慎决定，不涉及对德勤审计质量的任何异议。董事会与审核委员会认为，此举符合公司及股东整体利益，可确保2026年度审计工作在中国准则下顺利进行并避免重复审计成本。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hxpharma.com","stockEarnings":[{"period":"1week","weight":-0.1149},{"period":"1month","weight":-0.0944},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.1388},{"period":"1year","weight":1.0324},{"period":"ytd","weight":0.2912}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0761},{"period":"6month","weight":-0.0047},{"period":"1year","weight":-0.0507},{"period":"ytd","weight":-0.0311}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"福建海西新药创制股份有限公司成立于2012年3月27日。公司是一家处于商业化阶段的制药公司,集研发、生产及销售能力于一体,具备在研创新药的管线。公司在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。截至最后实际可行日期,公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药。根据灼识咨询的资料,该等治疗领域占2023年中国医药销售总额的25%以上。公司的创新药管线专注于具有各种适应症的在研药物,包括一款潜在属同类首款的在研肿瘤药物、一款潜在用于治疗湿性年龄相关性黄斑变性(wAMD)╱糖尿病性黄斑水肿(DME)╱视网膜静脉阻塞(RVO)的首款口服药物及另外两款处于临床前阶段,用于治疗肿瘤及呼吸系统疾病的创新在研药物。公司所有在研创新药均由内部以专有方式开发及发展。","exchange":"SEHK","name":"海西新药","nameEN":"HAIXI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海西新药,02637,海西新药股票,海西新药股票老虎,海西新药股票老虎国际,海西新药行情,海西新药股票行情,海西新药股价,海西新药股市,海西新药股票价格,海西新药股票交易,海西新药股票购买,海西新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}